FDA Accepts Recros Medica De Novo Submission for Nuvellus Focal Contouring System

Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus™, which utilizes the company’s proprietary Rotational Fractional Resection (RFR) technology, may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.

Recros Medica Showcases Interim Data on Rotational Fractional Resection Technology at 2018 ASDS

SAN DIEGO, Oct. 9, 2018 /PRNewswire/ — Recros Medica, Inc. announced today it will showcase its Rotational Fractional Resection (RFR) platform at the 2018 American Society for Dermatologic Surgery Annual Meeting. This investigational technology which is being developed as the Nuvellus™ Focal Contouring System for use by dermatologists, plastic surgeons and other aesthetic physicians to […]

Recros Medica Announces New Patent Issued by USPTO

SAN DIEGO, June 19, 2018 /PRNewswire/ — Recros Medica, Inc., an aesthetic medical device company focused on developing devices to reduce skin laxity and improve focal contouring through its Rotational Fractional Resection platform technology, announced today that the US Patent and Trademark Office has issued a new patent for a system that includes an array of circular cutting […]

Recros Medica Closes $9M Financing, Strengthens Board

SAN DIEGO, CA, January 4, 2018 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring, announced today that it has closed a $9M financing. Additionally, the company is strengthening its Board of Directors with the additions of Christoph Westphal, MD, PhD and Mark Kerslake. “We […]

Recros Medica Appoints Thomas A. Albright as President and CEO

SAN DIEGO, CA, September 18, 2017 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring, announced today that Thomas A. Albright has been named President and CEO, and will also serve on the Company’s Board of Directors. Mr. Albright brings nearly 35 years of healthcare […]